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Xeroderma pigmentosum family G from Van,
Turkey had two severely affected children: a son
with multiple skin cancers who died at age 10
(XP67TMA), and an 8 y old daughter who began
developing skin cancer before 3 y of age (XP68TMA).
XP67TMA and XP68TMA cells were hypersensitive
to killing by ultraviolet and the post-ultraviolet DNA
repair level was 12±16% of normal. Host cell reactiva-
tion of an ultraviolet-treated reporter plasmid
cotransfected with a vector expressing wild-type XPC
cDNA assigned XP67TMA to xeroderma pigmento-
sum complementation group C. The XPC mRNA
level was markedly reduced. Sequencing of the 3.5 kb
XPC cDNA from XP67TMA showed a C±T mutation
in XPC exon 8 at base pair 1840. This mutation con-
verts the CGA codon of arginine at amino acid 579 to
a UGA stop codon resulting in marked truncation of
the 940 amino acid xeroderma pigmentosum C
protein. Restriction fragment length polymorphism
analysis of XPC exon 8 DNA in XP67TMA and
XP68TMA showed that both affected children had a
homozygous mutation and that both parents had het-
erozygous normal and mutated sequences at the same
position consistent with a history of consanguinity in
the family. The mutated allele also contained two
XPC single nucleotide polymorphisms. The same
mutated XPC allele was reported in an Italian family.
Studies of 19 microsatellite markers ¯anking the XPC
gene on chromosome 3 suggest that the XPC allele
passed between Italy and Turkey approximately 300±
500 y ago. This XPC allele containing a nonsense
mutation is associated with severe clinical disease
with multiple skin cancers and early death. Key words:
DNA repair/microsatellite markers/skin cancer/SNP/UV
radiation. J Invest Dermatol 117:197±204, 2001
X
eroderma pigmentosum (XP) is a rare human
autosomal recessive disease characterized clinically
by severe hypersensitivity to sunlight, abnormal
pigmentation, and marked predisposition to skin
cancer (Bootsma et al, 1998; Van Steeg and
Kraemer, 1999). XP patients have an inherited defect in their
DNA nucleotide excision repair system, and the rate of skin cancers
is increased more than 1000-fold in comparison with normal
individuals (Kraemer et al, 1984, 1987, 1994). Ultraviolet (UV)
radiation exposure of human cells results in DNA damage
consisting primarily of cyclobutane pyrimidine dimers and 6-4
photoproducts. This damage is normally repaired by nucleotide
excision repair thereby preventing cell death, mutation or
carcinogenic transformation. XP patients have at least seven
different genetic defects (XP complementation groups A±G)
leading to defective DNA nucleotide excision repair. An additional
form, the XP variant (XP-V), has clinical XP with defective DNA
postreplication repair (Bootsma et al, 1998). These studies of XP
strongly imply that DNA nucleotide excision repair plays an
important part in the protection of sunlight-induced skin cancer
(Kraemer, 1997).
Sixteen XP patients in eight families have been reported in the
eastern part of Turkey (Dilek et al, 2000; Metin et al, 2000) We
studied one of the families (family G) from Van, Turkey that had
two children affected with severe XP. UV survival studies,
unscheduled DNA synthesis and host cell reactivation experiments
showed that family G was in XP group C (XP-C). In order to
determine the molecular defect in this family, the DNA and RNA
was isolated, and the XPC gene was ampli®ed and sequenced. We
found a nonsense mutation in exon 8 of the XPC gene in the
affected family members and two marker polymorphisms.
Remarkably, this same mutated XPC allele containing the marker
polymorphisms was recently reported in an Italian family
(Chavanne et al, 2000). We performed analysis of microsatellite
markers surrounding the XPC gene on chromosome 3 to
determine the possible time frame for the migration of this allele
between Italy and Turkey.
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MATERIALS AND METHODS
Cells and DNA donors Biopsy samples were obtained from the
ventral side of the upper arms of XP patients XP67TMA and
XP68TMA and their parents. (TMA refers to Malatya, Turkey the
location of the laboratory of E.G.) The biopsies were sent to the Human
Genetic Mutant Cell Repository, Camden, NJ for establishment of cell
lines: XP67TMA (GM14867), XP68TMA (GM14869), XPH96TMA
(GM15707) father, and XPH97TMA (GM15721) mother. These
®broblast cell lines and repair pro®cient ®broblast (GM0637) and
lymphoblast lines (AG10107) were obtained from the Human Genetic
Mutant Cell Repository. The ®broblasts were grown in Dulbecco's
modi®ed Eagle's medium supplemented with 10% fetal bovine serum
and L-glutamine (Gibco-BRL, Gaithersburg, MD) in an 8% CO2
humidi®ed incubator as described previously (Bredberg et al, 1986).
DNA from ®broblast cultures of XP10PV and her parents (Chavanne
et al, 2000) was extracted in Pavia and sent to Bethesda for further
analysis. A sample of convenience of buccal swabs was obtained for
DNA analysis from 84 unscreened anonymous donors (men and women
employees and unrelated children, age range 1±76 y) at the National
Institutes of Health (NIH), Bethesda, MD (Khan et al, 2000). XP patients
were excluded from these samples.
Cell survival Brie¯y 150,000 cells were plated in duplicate wells of a
six-well culture chamber. Twenty-four hours later the medium was
aspirated and cells were washed twice with phosphate-buffered saline
without calcium and magnesium and UV irradiation was performed on
ice with an un®ltered germicidal lamp at doses of 4, 8, 12, and 16 J per
m2 as described previously (Kraemer et al, 1989). Three days later the
cells were counted in a Coulter counter and the number of cells were
calculated in each well.
Northern blotting of XPC mRNA Total cytoplasmic RNA was
isolated from cells using RNA zol (Gibco-BRL) as per the vendor's
protocol. RNA (20 mg) was separated by electrophoresis and transferred
to a positively charged nylon membrane. Northern blot hybridization
was performed as described (Khan et al, 1998) using a 32P-labeled XPC
cDNA fragment 3.5 kb in size. Autoradiographic band intensities were
measured with a laser densitometer (Molecular Dynamics, Sunnyvale,
CA). After stripping off the XPC probe the same membrane was re-
probed with b-actin cDNA as an internal standard.
Host cell reactivation assay for DNA repair and complementation
group assignment Host cell reactivation, the ability of the XP cells to
repair a UV damaged plasmid, was used to measure the DNA repair
defect and to determine the XP complementation group. The XP and
normal cells were transfected with a UV-treated plasmid, pRSV-CAT,
containing the gene for chloramphenicol acetyltransferase (CAT) (Protic-
Sabljic and Kraemer, 1985). Three days later the cells were harvested by
scraping and the CAT activity and protein concentration was determined
(Khan et al, 1998). Enzyme activity was expressed as nmol per min per
mg protein. DNA repair de®cient cells are unable to repair the UV-
treated plasmid and have less CAT expression than normal cells.
The XP complementation group was determined by cotransfecting the
UV-treated pRSV-CAT plasmid with an expression vector containing
different cDNA of DNA repair genes (XPA, XPC, or XPD or pEBS7 as
an empty vector control) (Carreau et al, 1995; Khan et al, 1998).
Complementation of the XP DNA repair defect by a speci®c plasmid
increases the post-UV CAT expression and indicates the complementa-
tion group of the XP cells. All experiments were performed in duplicate.
The XPC-1601C plasmid (pXPC-3) was a generous gift from Dr. R.
Legerski (MD Anderson Center, TX) and contains XPC cDNA that
harbors a cytosine at position 1601 in exon 8. We also cloned another
XPC cDNA that carries a T at position 1601 in exon 8 (a generous gift
from Dr. Hanaoka) into the same expression vector (pXPC-1601T).
Both vectors were assayed for their host cell reactivation complementa-
tion ability as described in the ``XPC allele-speci®c complementation
assay'' (Khan et al, 2000).
Reverse transcriptase±polymerase chain reaction (reverse
transcriptase±PCR) and XPC nucleotide sequencing DNA and
RNA was isolated from the cells by using DNA zol and RNA zol
(Gibco-BRL) according to the manufacturer's protocol. The ®rst strand
cDNA was synthesized by utilizing 2 mg total RNA, oligo dT, and
reverse transcriptase (Gibco-BRL) as described (Khan et al, 1998) and
was utilized to amplify the entire coding region of XPC gene in
fragments as described (Li et al, 1993). Ampli®ed XPC gene regions were
separated by agarose gel electrophoresis and XPC cDNA bands were
extracted from the gel by using QIAquick gel extraction procedure
(Qiagen, Santa Clara, CA). The puri®ed DNA was sequenced by cycle
sequencing employing dideoxy termination chemistry using an ABI
373A DNA sequencer (Perkin Elmer-Applied Biosystem, Foster City,
CA).
Detection of XPC stop codon mutation in DNA by restriction
fragment length polymorphism assay The C1840T mutation region
in the exon 8 of the XPC DNA was PCR ampli®ed utilizing exon 8
primers: S1 (forward) 1770 5¢-TCTGACCTGTTACAAGTACG-3¢
1789 and S2 (reverse) 1882 5¢-TCACTGTCATCCAGACTG-3¢ 1865.
The PCR reaction was performed in a 50 ml volume containing 100±
200 ng DNA, 5 ml of 10 3 PCR reaction buffer, 1 ml of 50 3
deoxyribonucleotide triphosphate mix, 1 ml of advantage cDNA
polymerase mix and 100 ng of each primers (Advantage cDNA PCR kit,
Clontech Laboratories, Palo Alto, CA). The PCR steps were conducted
as follows: 94°C for 1 min, then 35 cycles of ampli®cation (94°C for
20 s and 68°C for 3 min), ending with 68°C for 3 min. The mutation
was analyzed by restriction enzyme digestion separately with DdeI and
Sau96I (New England Biolabs, Beverly, MA) of the PCR products
ampli®ed from DNA isolated from family members using S1 and S2
primers. The T at position 1840 of the XPC cDNA creates a DdeI site
and at the same time inactivates Sau96I site. The digested PCR products
were resolved on a 2% agarose gel. The gel was stained with ethidium
bromide and photographed under UV light.
Detection of XPC exon 8 and exon 15 polymorphisms The
frequency of XPC exon 8 T1601C DNA polymorphism was measured
by PCR ampli®cation of this region using forward primer S80 (5¢-
AGCCTCTGATCC CTCTGATG-3¢) and reverse primer S81 (5¢-
TCTTTTTTCTGCCTTCTCACC-3¢) of DNA obtained from buccal
swabs. DNA was extracted from buccal swabs by alkaline lysis as
previously described (Richards et al, 1993). The PCR reaction was
performed in a volume of 50 ml containing 1 3 PCR buffer, 1.5 mM
MgCl2, 200 mM of each deoxyribonucleotide triphosphate, 1 U Taq
DNA polymerase (Gibco-BRL), 100 ng of each primer, and 50±200 ng
DNA. The PCR was conducted under the following conditions: 94°C
for 60 s, then 35 cycles of ampli®cation (94°C for 15 s, 58°C for 30 s,
and 72°C for 150 s), ending with 72°C for 10 min. The polymorphic
position was analyzed by BsrI restriction endonuclease (New England
Biolabs) digestion of the 217 bp PCR products ampli®ed from donor
DNA using primer pairs S80 and S81. The T at position 1601 of the
XPC cDNA creates a BsrI site. BsrI digestion converts the 217 bp PCR
product into two fragments of size 75 bp and 142 bp. The fragments
were resolved on 2% agarose gel and photographed under UV light after
staining with ethidium bromide.
XPC exon 15 A2920C DNA polymorphism was determined by PCR
based ampli®cation of this region and subsequently digestion of the PCR
products with PvuII restriction endonuclease as described (Khan et al,
2000).
Microsatellite analysis Microsatellite markers (sequence tagged sites-
STS) on chromosome 3 ¯anking the 3p25 location of XPC were
identi®ed by use of the UniSTS website http://www.ncbi.nlm.nih.gov/
genome/sts/of the National Center for Biotechnology Information and
their linked maps of the human genome. We identi®ed 15 STS spanning
a range of 50 cM (Table I) and used the primers as listed on the
website. We identi®ed four new microsatellite markers in contigs
¯anking contig NT_006037 that contains the XPC gene on
chromosome 3. In the following primer pairs, the number after the
``NT'' is the contig designation and the number after the ``B'' is the
location of the ®rst base of the ``CA'' or ``GT'' repeats:
M3-NT_022498-B145447 (GenBank accession number: G7699) forward
primer: 5¢-GCAGCAGAGAGAGGTTCAAG-3¢, reverse primer: 5¢-
AGGCACACGGAGAGAAACAG-3¢.
M3-NT_005681-B2763 (GenBank accession number: G67701) forward
primer: 5¢-TGAAAGCTCTGCCTCTCCAC-3¢, reverse primer: 5¢-
ACACCTTACAACTCTCGCAC-3¢.
M3-NT_005681-B84724 (GenBank accession number: G67700) forward
primer: 5¢-ACACACAAGAGCACACATCC-3¢, reverse primer: 5¢-
GGCTGTTATTGTTTCCCCG-3¢.
M3-NT_005681-B207255 (GenBank accession number: G67702) for-
ward primer: 5¢-GAGTTAACCCCTGAGAGGTG-3¢, reverse primer:
5¢-TCAGTAAGGAGAGGGAAAGTAG-3¢.
DNA was isolated using DNAzol reagent (Gibco-BRL) as per the
manufacturer's protocol and microsatellite markers were genotyped using
¯uorescently labeled oligonucleotide probes. The genotyping was per-
formed blind to the inclusion status of the probands and to family
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information. PCR conditions were optimized. All the unlabeled anti-
sense and FAM-labeled sense primers ¯anking the microsatellite markers
were obtained from Research Genetics (Huntsville, AL). PCR ampli®ca-
tion for 17 of 19 microsatellite markers (as represented in Table I) was
carried out in a ®nal volume of 20 ml consisting of 30 ng genomic
DNA, 2 ml of 10 3 PCR buffer, 0.4 ml of 50 3 deoxyribonucleoside
triphosphate mix, 0.4 ml of Advantage cDNA polymerase mix
(Advantage cDNA PCR kit, Clontech Laboratory) and sense and anti-
sense primers of the following concentrations: 30 ng of each custom
made sense and anti-sense primers or 0.5 ml of 8 mM map pairs as
supplied (Research Genetics). The initial step for DNA polymerase was
carried out at 95°C for 2 min, followed by 26 cycles of 94°C for 45 s,
57°C for 45 s, and 72°C for 1 min. The ®nal extension was at 72°C for
7 min. The ®nal volume of the PCR was same for two other
microsatellite markers, D3S3726 and D3S1283, but the conditions were
different. Initial activation for DNA polymerase was carried out at 96°C
for 4 min, followed by 30 cycles at 95°C for 45 s, 52°C for 1 min, and
72°C for 1 min. Final extension was conducted at 72°C for 7 min. The
reactions were performed on a PTC-200 DNA Engine thermocycler (MJ
Research, Watertown, MA). PCR products were injected into an ABI
Prism 3100 Genetic Analyzer (Perkin Elmer-Applied Biosystems) in a
®nal volume of 11 ml consisting of 10 ml loading solution (19 parts of
deionized formamide, 1 part of GeneScan 500 ROX, size standard from
Perkin Elmer-Applied Biosystems) plus 1.0 ml PCR products. The
products were analyzed with the GeneScan, version 3.1.2, software
(Perkin Elmer-Applied Biosystems).
RESULTS
Case reports The 8 y old boy XP67TMA (Fig 1A) was referred
to the dermatology clinic in Van, in eastern Turkey because of sun
sensitivity and multiple skin cancers. He had abnormal skin lesions
by 1 y of age and developed typical freckling on sun-exposed areas
with atrophy, telangiectasia, hypopigmentation and actinic
keratoses. He had his ®rst skin cancer at age 6 y and subsequently
developed other tumors (two squamous cell carcinomas and one
atypical ®broxanthoma). He had no neurologic abnormalities.
He died at age 10 y from infection-complicated carcinomas.
XP67TMA was the second oldest of six children (Fig 2).
The 34 y old mother and the 39 y old father had a common
male ancestor four generations removed from the patient (Fig 2).
Both parents were in good health without any medical problems. A
5 y old sister (XP68TMA) demonstrated abnormal skin lesions
beginning at 6 mo (Fig 1B). She developed a squamous cell cancer
at age 2 y. A cousin began developing similar skin symptoms at 2 y
of age. He had squamous cell carcinoma, basal cell carcinoma,
melanoma, and atypical ®broxanthoma, and died at age 16 y from
years of infection-complicated carcinomas.
The Italian patient, XP10PV, from Bologna in northern Italy
developed skin cancers beginning at age 4 y. She had ocular lesions,
including tumors and died at age 15 y. The parents were not
known to be consanguineous (Chavanne et al, 2000).
DNA repair, cell survival Post-UV unscheduled DNA synthe-
sis was found to be 16% of normal in XP67TMA and 12% of
normal in XP68TMA. This range of unscheduled DNA synthesis is
typical of XP-C (Van Steeg and Kraemer, 1999). XP67TMA and
normal ®broblasts were exposed to UV radiation and survival was
measured after 3 d (Fig 3A). The XP67TMA cells were
hypersensitive to UV radiation with 15% survival after 16 J per m2
in comparison to 65% survival with the normal ®broblasts.
Post-UV host cell reactivation: DNA repair and comple-
mentation group determination The DNA repair ability of
the XP cells was assessed by use of plasmid host cell reactivation.
This assay measures the ability of the transfected cells to repair
plasmid DNA that was damaged by UVC. Repair is determined by
the expression of the marker gene, CAT contained in the UV-
treated plasmid. The XP cells and repair pro®cient normal cells
were transfected with pRSV-CAT plasmid treated with 500 J per
m2 or 1000 J per m2 UVC. Three days later CAT activity was
determined as described previously (Khan et al, 1998). The
XP67TMA cells showed much less CAT expression with the
UV-treated plasmid than the normal cells re¯ecting their DNA
repair defect (Fig 3B).
We then determined the XP complementation group by
cotransfection of the UV-treated plasmid with expression vectors
containing XPA, XPC, or XPD genes. Figure 3(B) shows
increased DNA repair activity when the XPC gene was transfected
into XP67TMA and XP68TMA cells. This result indicates that
these cells are in the XP-C complementation group.
cDNA analysis and XPC mRNA level RNA was isolated and
northern blot analysis showed markedly reduced XPC mRNA level
in XP67TMA cells in comparison with the normal cells (Fig 4A).
Table I. Molecular genetic analysis of XPC alleles and ¯anking markers
Genethon (cM) Microsatellite marker symbol
Turkish alleles Italian alleles
Paternal Maternal Paternal Maternal
0 D3S1270(+) 5 5 5 4
1.4 D3S1307(+) 1 1 2 1
2.5 D3S1297(+) 1 4 3 4
D3S1515(+) 1 3 2 1
16.5 D3S1304(+ 3 4 2 2
24.1 D3S1597 3 1 4 4
30.9 D3S1263 3 2 4 3
30.9 D3S1259 2 3 3 3
M3-NT_022498-B145447 2 2 1 1
33 D3S1585 1 1 1 1
XPC C1840T ARG579STOP stop stop stop stop
XPC T1601C VAL499ALA C C C C
XPC A2920C LYS939GLU C C C C
M3-NT_005681-B2763 1 1 1 1
M3-NT_005681-B84724 2 2 2 2
36.8 D3S3726 2 2 2 2
35.7 D3S1554 4 4 1 1
M3-NT-005681-B20725 1 1 2 2
36.9 D3S1293 1 1 2 1
46.8 D3S1283 4 4 1 1
46.8 D3S1266 4 2 2 1
50.4 D3S3727 1 1 1 3
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cDNA was synthesized utilizing reverse transcriptase. We ampli®ed
and sequenced the entire 3558 bp XPC cDNA using 13 primers
(Legerski and Peterson, 1992). In XP67TMA cDNA two bands
were visualized in the region of exon 8 (Fig 4B). The upper band
contained full length exon 8. Sequencing revealed a G:C base pair
(Fig 4C) changed to A:T base pair in exon 8 at position 1840
(Fig 4D). This point mutation converts the CGA codon of
arginine at position 579 to a UGA stop codon. This change would
lead to a truncation of the XPC protein at amino acid 579 rather
than at its full length of 940 amino acids.
Sequencing showed that the lower band (Fig 4B) had a deletion
of 246 nucleotides from nucleotides 1732±1977 representing the 3¢
portion of exon 8. This represents a normal and not XP-related
alternatively spliced XPC mRNA variant. It utilizes a cryptic splice
donor site with an information content of 6.1 bits (Rogan et al,
1998) (analysis performed by use of the program developed by Dr
T. Schneider, which is accessible at http://www.lecb.ncifcrf.gov/
~toms/delilaserver.html).
Restriction fragment length polymorphism analysis of
DNA The G:C to A:T transition mutation at position 1840
created a new DdeI restriction site in XPC exon 8 (Fig 5). The
normal exon 8 would be cut by Sau96I restriction endonuclease
converting 113 bp PCR products into two fragments of size 67 and
46 bp but not cut by DdeI. In contrast, mutated exon 8 DNA
would be cut by DdeI converting the 113 bp PCR products into
two fragments of size 69 bp and 44 bp and not by Sau96I. In order
to determine whether the mutations in the XP patients were
homozygous or heterozygous exon 8 DNA was ampli®ed from
XP67TMA, XP68TMA, and normal cells by PCR. When these
three DNA samples were treated with Sau96I or DdeI, we observed
that XP67TMA DNA and XP68TMA DNA was cut only by DdeI
restriction endonuclease, but wild-type DNA was cut only by
Sau96I restriction endonuclease (Fig 5, top gel). These results
indicate that XP patients XP67TMA and XP68TMA both had the
same homozygous mutation in position 1840 in the XPC gene. [As
both parents were heterozygous for this same allele (see below), the
patients were not hemizygous with one mutated allele and the
other containing a deletion in that region.]
XPC exon 8 DNA was then ampli®ed from ®broblasts from both
parents, one of the affected children and a normal donor and treated
with Sau96I and DdeI restriction endonuclease (Fig 5, lower gel).
Whereas the DNA from the child was only cut by DdeI restriction
endonuclease, normal DNA was cut only by Sau96I restriction
endonuclease; however, the parents' DNA was cut by both DdeI
and by Sau96I restriction endonucleases. This result indicates that
both parents were heterozygous for the same mutation in that one
allele behaved like a wild type and the other one had a mutation in
1840 position like their children. Thus each parent was hetero-
zygous for the mutated and the wild-type XPC alleles.
Marker XPC polymorphisms in XP67TMA Two single
nucleotide polymorphisms (SNP) have been previously reported
in XPC cDNA from normal donors (Legerski and Peterson, 1992;
Li et al, 1993; Masutani et al, 1994; Chavanne et al, 2000; Khan
et al, 2000). The exon 8 variant T1601C results in amino acid
change of valine 499 to alanine and the exon 15 variant A2920C
changes lysine 939 to glutamine.
Using the host cell reactivation-based complementation assay we
determined that plasmids containing XPC cDNA with either a T or
C at position 1601 in exon 8 were fully functional in correcting the
XPC defect (Fig 3C). Similarly, both XPC exon 15 variants 2920A
and 2920C were shown to be fully functional (Khan et al, 2000).
We analyzed DNA from 84 donors (Table II) and found that
for the exon 8 T1601C polymorphism the C allele was present in
Figure 2. Pedigree of XP family G from Van, Turkey. Two of six
children, XP67TMA and XP68TMA, had XP with multiple skin cancers
(solid symbols). The parents, XPH96TMA and XPH97TMA (half ®lled
symbols), have a common ancestor four generations removed from the
affected children. The half ®lled symbols in generations II, III, and IV
indicate the probable inheritance of the XPC allele containing the stop
codon.
Figure 1. Turkish XP patients. (A) The 7 y old boy, XP67TMA, has
numerous freckle-like pigmented lesions of varying size, shape, and
intensity interspersed with areas of hypopigmentation, telangiectasia, and
atrophy on sun-exposed portions of the face, lips, ears, upper chest, and
neck. His lips show cheilitis. There is conjunctival injection and his
lower eyelids have ectropion and loss of lashes. He had multiple cancers,
including squamous cell carcinomas on his face. He died at 10 y of age.
(B) His 5 y old sister, XP68TMA, shows similar but less severe changes
on the skin of her face, neck, and anterior chest with sparing of sun-
protected parts of her chest and arms. There is early ectropion and loss
of lashes of her lower eyelids. She had a squamous cell carcinoma on her
face excised at age 2 y.
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76.8% of the alleles examined and for the exon 15 A2920C
polymorphism the C allele was present in 40.5% of the alleles. The
combination of homozygous C/C in exon 8 and C/C in exon 15
was found in 20% of the donors (Table II). There was nonrandom
association of these polymorphic alleles (p < 0.001 by using the
Pearson chi-square test).
Sequencing of the XP67TMA cDNA found two base substitu-
tions: T at base pair 1601 in exon 8 was changed to a C in both
alleles (Fig 4D right) and the A at base pair 2920 in exon 15 was
changed to a C in both alleles. In the father's cells, XPH96MA,
base pair 1601 was C and base pair 2920 was C in both alleles. In
the mother's cells, XPH97MA, base pair 1601 was heterozygous
with C in one allele and T in the other and base pair 2920 was
similarly heterozygous for C in one allele and A in the other. These
polymorphic mutations are not responsible for the functional defect
in the XP67TMA cells but may serve as markers of the allele
containing the causative mutation. Thus the allele containing the
stop codon C1840T in exon 8 also contains polymorphisms at
T1601C in exon 8 and A2920C in exon 15.
Microsatellite analysis The XP patients in Turkey (XP67TMA
and XP68TMA) (this study) and Italy (XP10PV) (Chavanne et al,
2000) were homozygous for the same XPC stop mutation at
Arg579 in exon 8, as well as the T1601C polymorphism in exon 8,
the A2920C polymorphism in exon 15 (Table I) and the deletion
of the 3¢ end of exon 8. This suggested the possibility that they
might share a common ancestor. We used a molecular genetic
approach involving microsatellite markers (Gyapay et al, 1994;
Shevchenko et al, 2000) to test this hypothesis.
We identi®ed 15 previously reported polymorphic microsatellite
markers on chromosome 3 that span 50 cM ¯anking the XPC gene
(Table I). We generated four new polymorphic markers located in
contigs adjacent to the XPC gene and assessed their heterozygosity
in DNA from nine normal donors. M3-NT_022498-B145447 has
eight alleles and a heterozygosity of 0.80. M3-NT_005681-B2763
has three alleles and a heterozygosity of 0.36. M3-NT_005681-
B84724 has two alleles and a heterozygosity of 0.50. M3-
NT_005681-B207255 has four alleles and a heterozygosity of 0.70.
The patients in Turkey and Italy were homozygous for allele 1
for marker D3S1585, allele 1 for M3-NT_005681-B2763, allele 2
for M3-NT_005681-B84724, and allele 2 for D3S3726 as well as C
for the exon 8 SNP and C for the exon 15 SNP (dark black shading
in Table I). Based on allele frequencies calculated from control
chromosomes, the probability of the random occurrence of this
homozygous genotype of four microsatellite markers and two SNP
was 5 3 10±5.
The alleles from the Italian patient were homozygous from
D3S1259 to M3-NT_005681-B20725 along chromosome 3 (light
gray shading in Table I). The alleles from the Turkish family were
homozygous for a larger region: from M3-NT_022498-B14544 to
D3S1283 (dark gray shading in Table I).
Figure 3. Post-UV cell survival and in vivo complementation with
the XPC gene assigning XP67TMA cells to XP-C. (A) Post-UV
cell survival of XP67TMA and normal cells. Survival of the XP67TMA
cells (solid squares) is lower than that of the normal cells (open circles).
(B) Host cell reactivation assay for DNA repair and complementation
group determination. UVC-treated pRSVcat plasmid was either
transfected with control plasmid pEBS7 (solid symbols) or with pXPC
(open symbols) into triplicate cultures of XP67TMA (circles) or
XP68TMA (squares) primary skin ®broblasts. Each symbol represents the
relative CAT activity in an independent transfection compared with the
corresponding untreated plasmid (Khan et al, 1998) corrected by addition
of the plasmid expressing the XPC cDNA. (C) Functional assessment of
the T1601C XPC polymorphism. UVC-treated pRSVcat plasmid was
either transfected alone (circle) or with pXPC-1601T (diamond) or
pXPC-1601C (triangle) plasmid into triplicate cultures of XP4PA-SV-EB
®broblasts (XP-C patient cells). Each symbol represents the relative CAT
activity in an independent transfection compared with the corresponding
untreated plasmid (Khan et al, 1998). Both plasmids are fully functional
in correcting the XP-C defect.
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DISCUSSION
XP distribution world-wide XP is an autosomal recessive
disorder that has been found in all races world-wide. A survey of
the medical literature from the original report in 1874 to 1982
revealed 830 published cases (Kraemer et al, 1987). There were
many reports from the United States (241 cases), Europe (210
cases), Japan (91 cases), and Egypt (49 cases). Only 18 cases (2.2%)
were reported from Turkey. A later study reported on clinical and
laboratory features of 262 Japanese patients (Takebe et al, 1987). As
is often seen in recessive disorders, consanguinity of the patient's
parents was common occurring in about 30% of both studies. XP
family G from Van, Turkey had two severely affected children and
an affected cousin. All three patients experienced typical symptoms
of XP with early onset of sunlight induced pigmentary changes
Figure 4. Analysis of XPC in XP67TMA and normal cDNA. (A)
Northern blot analysis shows markedly reduced XPC mRNA level in
XP67TMA compared with normal cells. There is a similar level of actin
in both cells. (B) RNA was puri®ed and the XPC exon 8 region was
ampli®ed by reverse transcriptase±PCR. Agarose gel electrophoresis of
exon 8 region shows a normal sized (671 bp) band in the normal cells
and both the 671 bp band and a 245 bp shorter band in XP67TMA
cells. (C) DNA sequencing was performed with cDNA from the normal
cells. Left: The DNA from the normal donor shows a G:C base pair at
base pair 1840 (vertical arrow). The CGA codes for an arginine at amino
acid 579. [Note use of reverse primer for sequencing. Base pair position
1 corresponds to the beginning of the 5¢ untranslated region of the XPC
cDNA as indicated in GenBank sequence D21089 (Masutani et al, 1994)]
Right: In normal cells base pair 1601 is heterozygous for A:T and G:C
base pairs (vertical arrow). The GTG sequence codes for valine at amino
acid 499, whereas GCG codes for alanine in this exon 8 marker
polymorphism. (D) DNA sequencing was performed with cDNA from
the XP67TMA cells. Left: The DNA from XP67TMA shows an A:T
base pair at base pair 1840 (vertical arrows). This homozygous transition
mutation changes the CGA codon of arginine 579 to a TGA stop
codon. Right: In XP67TMA cells base pair 1601 is homozygous for G:C
resulting in the GCG codon for alanine at amino acid 499 the exon 8
marker polymorphism.
Figure 5. Restriction fragment length polymorphism determin-
ation of mutation in XPC exon 8 in members of XP family G.
DNA was isolated from cells from XP67TMA, XP68TMA, and their
parents. A 113 bp region of XPC exon 8 was ampli®ed, digested with
the restriction endonucleases Sau96I or DdeI, and the products were
separated by agarose gel electrophoresis. Sau96I only cuts the normal
sequence into two fragments, whereas DdeI only cuts the mutant
containing the G:C to A:T mutation at position 1840 (bottom of ®gure).
XP67TMA and XP68TMA DNA is only cut by DdeI, whereas the
DNA from the normal donor is only cut by Sau96I (top gel). The DNA
from both parents yield three bands with each enzyme indicating the
presence of a normal allele and an allele with the G:C to A:T mutation
at position 1840 (lower gel).
Table II. Linkage disequilibrium between XPC exon 8 and
XPC exon 15 polymorphisms in 84 NIH donors.
XPC exon 15 A2920C Lys939Glu genotype.
Number of donors with indicated genotypea
(Expected numbers under equilibrium)
XPC exon 8 T1601C
Val499Arg genotype
C/C C/A
A/A
C/C
C/T
17 (8.1)
0(4.9)
17(23.9)
17(14.4)
13(17.5)
18(10.6)
T/T 0(0.7) 0(2.2) 2(1.6)
aSigni®cantly different from expected numbers p < 0.001 (Pearson chi-square
test).
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followed by skin cancers at an early age. The affected son died at
age 10 and the cousin died at age 16 y. The parents were related to
each other.
XP and DNA repair The severe symptoms of XP are caused by
a defect in DNA repair. The nucleotide excision repair system
recognizes damaged DNA, removes the lesion and then ®lls in the
resulting gap of about 30 nucleotides (Van Steeg and Kraemer,
1999).
Seven of the proteins involved in nucleotide excision repair
(XPA-XPG) have been found to result in clinical XP when
mutated (Kraemer, 1999a, b) These have been called complemen-
tation groups A±G. The frequency of different complementation
groups varies in different parts of the world. Whereas XP-A is most
common in Japan (Takebe et al, 1987), XP-C and XP-D are more
common in Europe and the U.S.A. (Bootsma et al, 1998). The
DNA repair defects in XP patients from Turkey have not
previously been characterized. This family has a defect in XP-C.
The XPC protein plays a part in DNA lesion recognition (Emmert
et al, 2000) and in repair of DNA in the global genome (Bootsma
et al, 1998).
The DNA repair defect in XP cells is manifest by increased
sensitivity to cell killing by UV (Fig 3A) and by the reduced
unscheduled DNA synthesis (12±16% of normal in XP67TMA and
XP68TMA). XP cells are unable to repair DNA damage in UV-
treated plasmids. This host cell reactivation assay can be used to
determine reduced DNA repair and to determine the comple-
mentation group by cotransfection with a vector expressing DNA
repair genes (Fig 3B) (Khan et al, 1998). The XP67TMA and
XP68TMA cells were corrected by transfection of the XPC gene
thereby indicating a XPC DNA repair defect.
XPC mutations Mutations in the XPC gene have been reported
in only 19 patients (Li et al, 1993; Khan et al, 1998; Cleaver et al,
1999; Chavanne et al, 2000; Slor et al, 2000). Most of the mutations
reported that appear to be related to the clinical disease result in
premature termination of the XPC protein. These include
frameshifts, nonsense mutations, and splice defects. Patient
XP67TMA had a C to T nonsense mutation at base pair 1840
that results in conversion of the arginine codon at amino acid 579
to a stop codon. This would result in marked truncation of the
XPC protein at amino acid 579 rather than at its full length of 940
amino acids. This results in the observed markedly reduced level of
XPC mRNA because of a process known as ``nonsense mediated
message decay'' (Nagy and Maquat, 1998) This shortened
polypeptide would be expected not to function to correct the
DNA damage by nucleotide excision repair thus resulting in the
severe clinical disease seen in family G. Analysis of the DNA by
sequencing and restriction endonuclease digestion revealed that this
mutation was homozygous in both patients.
XPC allele with nonsense mutation in Turkey and
Italy This same C1849T nonsense mutation in exon 8 was
recently reported in a family from Italy (Chavanne et al, 2000). The
Italian patient, XP10PV, had 20% of normal DNA repair synthesis.
She began developing skin cancers at age 4 y and had skin and eye
involvement. She died at age 15 y. This low DNA repair level and
severe clinical course is similar to that of XP67TMA and the other
affected individuals in Turkish family G (Figs 1 and 2). The DNA
repair level was 12±16% of normal and one cousin died at age 16 y,
a son died at age 10 and the third affected child began developing
skin cancers at 2 y of age. The mutated XPC allele in XP67TMA
shares the same homozygous T1601C polymorphism in exon 8 and
homozygous A2920C polymorphism in exon 15 as the Italian
XP10PV patient. In addition, both have an alternatively spliced
XPC mRNA message with a deletion of the 3¢ end of exon 8 (del
amino acids 543±624). This XPC allele thus is associated with a
severe clinical phenotype in two families in different countries.
Could this same XPC allele have arisen spontaneously in both
Turkey and Italy? The defective allele has a mutated C at position
1840, which is part of a CpG DNA sequence that has been
implicated in C to T transitions. This is presumably the result of
demethylation of 5-methylcytosine to thymine. This mutation
might have appeared spontaneously in the XPC allele in Turkey
and again in Italy. XP67TMA and XP10PV are also homozygous
for two single nucleotide polymorphisms in the XPC gene:
T1601C in exon 8 and A2920C in exon 15. These sequence
variations alter amino acids (Valine499 to Alanine and Lysine939 to
Glutamine, respectively) but do not change the function of the
gene (Khan et al, 2000) and Fig 3(C). These common single
nucleotide polymorphisms are not in CpG sequences and occur at a
frequency of about 77% and 40%, respectively, in unselected
donors (Table II). The combination of homozygous C/C in exon
8 and C/C in exon 15 was observed in 20% of the donors
(Table II). It is possible that the putative alleles that acquired the
C1840T mutation already had both polymorphisms.
Both families, however, have a larger region of chromosome 3 in
common (Table I). Based on allele frequencies calculated from
control chromosomes, the probability of the random occurrence of
this homozygous genotype of four microsatellite markers and two
SNP was 5 3 10±5. It is thus very unlikely that this speci®c
combination of alleles would have occurred spontaneously both in
Turkey and in Italy. As cells from the Turkish patients, XP67TMA
and XP68TMA, and the Italian patient, XP10PV, were homo-
zygous for the C1840T mutation, they received the same defective
allele from each parent. This suggests that the patients in both
families had a common ancestor. The molecular genetic analysis
described below provides support for this hypothesis.
Estimation of genetic relationships using microsatellite
markers We used microsatellite markers to assess possible
genetic relationships between the families in Turkey and Italy.
Microsatellite markers are de®ned as regions of DNA of known
location that contain repetitive sequences such as (CA)n or (GT)n
where n may be up to 20 or more [e.g., M3-NT_022498-B145447
has (GT)24] (Gyapay et al, 1994). These regions of the DNA may
show variation in the number of repeats in different individuals.
Variations in related individuals in different generations are usually
due to recombination during meiosis or cell division. This fact may
be used to determine the degree of relationship between different
individuals sharing some common genetic features (for discussion of
this approach see Shevchenko et al, 2000). Individuals that are
closely related will show larger regions of identity than people who
are more distant relatives. For example, we extended the
examination of DNA from the XP patient XP22BE (Khan et al,
1998) who had a history of consanguinity and determined that all
15 microsatellite markers tested were homozygous.
Hypothesizing that there was a single founder with the XPC stop
codon mutation and both XPC single nucleotide polymorphisms
and that the population expanded at a constant exponential rate,
permits use of the classical mutation analysis described by Luria and
Delbruck (1943) to estimate the number of generations that has
passed as the mutation was introduced into the population. The
formula:
(I) R = 1 ± e( ± gq)
may be used where R is the proportion of chromosomes carrying
the mutation in which recombination with the conserved
haplotype has occurred, g is the number of generations, and q is
the genetic distance between the recombined markers.
The parents in the Turkish family were known to be related;
therefore, they would have received the defective allele from a
recent common ancestor. Table I shows the 19 microsatellite
markers we used arranged along chromosome 3 as indicated by
current maps of the human genome http://www.ncbi.nlm.nih.
gov/. In the Turkish family the paternal and maternal alleles show a
region of identical alleles bounded by D3S1259 and D3S1266
(outside of dark gray shaded region in Table I). At these markers
there is 50% recombination (R = 0.5) and they are 15.9 cM apart
(q = 0.159). Solving formula I for g = 4 generations. This is in
striking agreement with the pedigree (Fig 2) that shows that the
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parents share a common relative four generations removed from the
affected children.
The Italian family of XP10PV was not reported to be
consanguineous, thus they may have received the defective allele
from a distant ancestor. The paternal and maternal alleles from the
Italian family show a region of identity smaller than that of the
Turkish family, which is bounded by D3S1263 and D3S1293
(lightly shaded region Table I). These markers show 50%
recombination and are 6 cM apart. This corresponds to g = 12
generations, which is consistent with the reported lack of
knowledge of a common ancestor by the parents of the Italian
patient.
Both families have a region of identity bounded by M3-
NT_022498-B145447 and D3S1554 (dark black shading Table I).
These markers show 50% recombination and are 4.8±2.7 cM apart.
This corresponds to g = 14±26 generations. If a generation is 20 y
this suggests the existence of a common ancestor about 300±500 y
ago.
There are many historical links between Turkey and Italy. The
Roman emperor Constantine established Constantinople as his
capitol in AD 330. The Ottoman Turks led by Fatih Sultan Mehmet
gained control in 1453 and changed the name to Istanbul. Van,
Turkey, the location of the Turkish patients near the eastern border
of Turkey is about 2000 miles from Bologna, in northern Italy, the
home of the Italian patient. It is possible that in the ®fteenth to
seventeenth century an ancestral founder carrying the C1840T
mutation along with the other two XPC marker polymorphisms
and adjacent microsatellite alleles was the source of the mutation in
both the Turkish and the Italian families. In its homozygous form
this allele is associated with severe clinical disease and early death.
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